Phase IIb study of cannabidiol for the prevention of acute Graft versus Host Disease GvHD following allogeneic hematopoietic cell transplantation (HCT).

Trial Profile

Phase IIb study of cannabidiol for the prevention of acute Graft versus Host Disease GvHD following allogeneic hematopoietic cell transplantation (HCT).

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Dec 2017 According to a Kalyteta Therapeutics media release, the principal investigator of the study is Daniel Couriel, M.D., M.S., Director of the Bone Marrow Transplant Program at the University of Utah Health Sciences, School of Medicine.
    • 07 Dec 2017 According to a Kalytera Therapeutics media release, results of the study are expected by Q3 2018.
    • 07 Dec 2017 According to a Kalyteta Therapeutics media release, status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top